Oncosec medical inc (ONCS)
CashFlow / Yearly
Jul'19Jul'18Jul'17Jul'16Jul'15Jul'14Jul'13Jul'12
Operating activities
Net loss

-30,276

-39,136

-21,449

-26,888

-21,243

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Net loss

-

-

-

-

-

-12,012

-7,150

-2,364

Depreciation and amortization

243

334

379

355

664

780

736

717

Loss on disposal of property and equipment

-0

-875

0

-203

-4

-

-

-

Warrant inducement expense

-

2,465

0

-

-

-

-

-

Amortization of discount on investments

51

28

0

-

-

-

-

-

Stock-based compensation

3,364

8,252

4,016

6,116

-

-

-

-

Stock-based compensation related to stock issuance liability in connection withacontractual agreement

-

-

-

-

55

-

-

-

Common stock issued for services

845

1,845

0

55

57

150

34

-

Modification of equity award

135

-

-

-

-

-

-

-

Foreign currency exchange loss, net

281

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

761

Gain on adjustment to fair value of derivative liabilities

-

-

-

-

-

-

-

4,192

Non-cash interest expense

-

-

-

-

-

20

83

266

Stock-based compensation

-

-

-

-

2,547

1,815

452

332

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-

-

130

-855

1,068

-

-

-

Common stock issued for services

-

-

-

-

-

-

-

249

Prepaid expenses and other current assets

1,209

-97

-

-

-

405

-156

164

Other current assets

357

593

-14

-6

2

-11

-30

-7

Other long-term assets

9

49

88

-24

187

-

-

-

Accounts payable and accrued liabilities

-741

1,427

-208

861

1,068

657

344

15

Accrued compensation related

-394

955

-128

-258

459

42

-218

151

Other long-term liabilities

-836

331

253

854

-12

-

-

-

Net cash used in operating activities

-29,003

-23,221

-17,340

-

-

-

-

-

Investing activities
(Decrease) Increase in accrued income taxes

-

-

-

-0

-0

-0

-1

1

Decrease in accrued other and taxes

-

-

-

-

-

-16

60

-

Net cash used in operating activities

-

-

-

-17,814

-17,651

-8,980

-5,533

-4,219

Purchases of property and equipment

9

65

21

1,470

1,412

512

114

54

Purchase of investment securities

-

25,474

-

-

-

-

-

-

Maturity of investment securities

17,236

2,250

0

-

-

-

-

-

Sale of investment securities

5,977

-

-

-

-

-

-

-

Purchase of investment securities

-

-

0

-

-

-

-

-

Net cash provided by investing activities

23,203

-23,289

-21

-

-

-

-

-

Financing activities
Leasehold improvements

-

-

-

80

-18

-

-

-

Net cash used in investing activities

-

-

-

-1,550

-1,431

-512

-114

-54

Proceeds from issuance of common stock through ESPP

27

35

0

-

-

-

-

-

Proceeds from issuance of common stock and/or warrants

27,897

32,283

0

17,451

-

-

-

7,750

Payment of financing and offering costs

1,159

3,575

15

1,381

-

-

-

-

Proceeds from exercise of options

566

321

79

-

-

-

-

-

Proceeds from exercise of warrants

-

9,999

0

6

-

-

-

-

Principal payments on note payable

81

-

-

-

-

-

-

-

Tax withholdings paid on equity awards

101

-

-

-

-

-

-

-

Tax withholdings paid related to net share settlement of equity awards

32

181

0

-

-

-

-

-

Tax shares sold to pay for tax withholdings on equity awards

-83

-

-

-

-

-

-

-

Repurchase of fractional shares

0

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

27,198

38,883

64

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-54

-12

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

21,344

-7,641

-

-

-

-

-

-

Proceeds from issuance of common stock and warrants

-

-

-

-

13,580

27,948

7,200

-

Payment of financing and offering costs

-

-

-

-

1,091

1,981

504

542

Payment of amounts due under acquisition obligation

-

-

-

-

-

-1,000

-1,500

-

Payment of amounts due under acquisition obligation

-

-

-

-

-

-

-

250

Proceeds from exercise of warrants and stock options

-

-

-

-

776

17,408

280

-

Net cash provided by financing activities

-

-

-

16,075

13,265

42,375

5,476

6,957

Effect of exchange rate changes on cash and cash equivalents

-

-

-3

0

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-17,301

-3,289

-

-

-

-

Net (decrease) in cash

-

-

-

-

-5,817

32,882

-171

2,683

Supplemental disclosure for cash flow information:
Interest

3

-

0

0

-

-

-

-

Interest

-

-

-

-

0

-

-

-

Income taxes

1

0

1

2

1

-

-

-

Income taxes

-

-

-

-

-

1

2

0

Noncash investing and financing transactions:
Fair value of placement agent warrants issued in the public offering

-

-

-

536

-

-

-

-

Expiration of warrants

4,060

1,200

1,479

963

-

-

-

-

Amounts accrued for offering costs

200

45

256

0

-

-

-

-

Note issued for insurance premium

185

-

-

-

-

-

-

-

Fair value of placement agent warrants issued in the publicofferings

-

-

-

-

571

-

-

-

Issuance of common stock in connection with a contractual agreement

-

-

-

-

-

1,042

228

276

Noncash expiration of March 2011 and June 2011 warrants

-

-

-

-

0

-

-

-

Acquisition obligation discounts - imputed interest and fair value of warrants

-

-

-

-

-

-

-

402